Noscapine

Drug Profile

Noscapine

Alternative Names: CB 3304; Narcotine; NSC 5366

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Emory University
  • Developer Cougar Biotechnology; University of Southern California
  • Class Alkaloids; Antineoplastics; Antitussives; Isoquinolines; Opiate alkaloids; Small molecules
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chronic lymphocytic leukaemia; Multiple myeloma; Non-Hodgkin's lymphoma

Most Recent Events

  • 10 Jul 2009 Cougar Biotechnology has been acquired by Johnson and Johnson
  • 22 Dec 2007 Phase-I/II clinical trials in Multiple myeloma in USA (PO)
  • 23 Jul 2007 Cougar receives allowance of IND for noscapine for the treatment of multiple myeloma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top